Are you altering your use of immune checkpoint inhibitors given the risk of immune-related pneumonitis and the COVID-19 outbreak?

Topics: Gynecologic Cancers • Pediatric Oncology • Medical Oncology • Immunotherapy • COVID-19

Answer from: Medical Oncologist at Academic Institution

The management of advanced cancer patients has gotten even more complex with the COVID-19 pandemic. In general, providers are trying to keep patients away from the hospital/clinic as much as possible, and avoiding regimens with greater toxicity if there are suitable less toxic alternatives. Whether ...

Comments

Medical Oncologist at Stamford Health
Agree. Facing this with my lung CA patients more t...

Medical Oncologist at University of Washington School of Medicine
Fully agree with @Brian I. Rini. This is clearly a...

Answer from: Medical Oncologist at Community Practice

Nivolumab can be used every 4 weeks rather than every 2 weeks. We have to be flexible and change our approach according to circumstances.

Related Questions